-
Tumori 1997
Review
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Mucin-1; Mucins
PubMed: 9226018
DOI: 10.1177/030089169708300214 -
British Medical Journal Sep 1951
Topics: Humans; Mucins
PubMed: 14869681
DOI: No ID Found -
Annales de Dermatologie Et de... 2016Mucinous nevus is a rare disease characterized by mucin deposits in the dermis, with only 23 cases reported to date. It belongs to the connective tissue nevus family...
INTRODUCTION
Mucinous nevus is a rare disease characterized by mucin deposits in the dermis, with only 23 cases reported to date. It belongs to the connective tissue nevus family and is characterized by dermal mucin deposits. Two histological subtypes have been described: pure mucinous dermal nevus (connective tissue nevus of the proteoglycan [CTNP]) and combined mucinous nevus (combined CTNP) associating epidermal nevus with dermal mucin deposits. Lesions generally appear in childhood or early adulthood. We report herein the case of a 59-year-old man with a symptomatic lesion.
OBSERVATION
A 59-year-old man consulted for unilateral lesions occurring linearly along the Blaschko line on the right lower limb, composed of brown verrucous papules, which started at the age of 50. The patient complained of itching caused by friction from clothes. Histological examination of a papule highlighted an acanthotic epidermis, with elongation of rete ridges and mucin deposits in the dermis showing uptake of alcian blue stain. The clinicopathological analysis enabled diagnosis of combined CTNP. We treated this nevus by surgical dermabrasion and observed a slight and cosmetically acceptable scar.
DISCUSSION
To our knowledge, our patient is the oldest reported to date and the only one to have complained of symptoms. Our review of the literature highlights the importance of skin biopsy to guide aesthetic or symptomatic treatment. CO2 laser and dermabrasion are recommended for combined CTNP as they treat the epidermal component with low risk of secondary scarring. However, these techniques should be avoided in pure dermal CTNP, where surgical excision alone is acceptable in order to achieve optimal cosmetic results.
Topics: Humans; Male; Middle Aged; Mucins; Nevus; Skin Neoplasms
PubMed: 27197785
DOI: 10.1016/j.annder.2016.03.017 -
Zhonghua Bing Li Xue Za Zhi = Chinese... Nov 2013
Review
Topics: Adenocarcinoma, Mucinous; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Lymphatic Metastasis; Mucin-1; Mucin-2; Mucins; WT1 Proteins
PubMed: 24447562
DOI: No ID Found -
Medical Oncology (Northwood, London,... Jun 2023Invasive mucinous adenocarcinoma (IMA) is a rare variant of adenocarcinoma with unique clinical, radiological, and pathological features, among which KRAS mutation is... (Comparative Study)
Comparative Study
Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.
Invasive mucinous adenocarcinoma (IMA) is a rare variant of adenocarcinoma with unique clinical, radiological, and pathological features, among which KRAS mutation is the most common. However, the differences in the efficacy of immunotherapy between KRAS-positive IMA and invasive non-mucinous adenocarcinoma (INMA) patients remain unclear. Patients with KRAS mutated adenocarcinomas receiving immunotherapy between June 2016 and December 2022 were enrolled. Based on mucin-producing status, the patients were placed into two subgroups: the IMA group and INMA group. Patients with IMA were further classified into two subtypes according to the presence of mucin patterns: pure IMA (≥ 90%) and mixed mucinous/nonmucinous adenocarcinoma (≥ 10% of each histological component). Kaplan-Meier Curves and log-rank tests were used to analyze survival. Cox regression analysis of PFS were used to analyze the independent factors associated with efficacy. Sixty-five advanced adenocarcinoma patients with KRAS mutations received immunotherapy, including 24 patients with IMA and 41 with INMA. The median progression-free survival (PFS) was 7.7 months, whereas the median overall survival (OS) was 24.0 months. Significant difference in PFS could be observed in IMA and INMA (3.5 months vs. 8.9 months; P = 0.047). Patients with pure IMA tended toward prolonger survival in contrast to mixed mucinous/nonmucinous adenocarcinoma in PFS (8.4 months vs. 2.3 months; P = 0.349). The multivariable analysis demonstrated that IMA was an independent risk factor for PFS. In KRAS mutated patients, IMA was associated with poorer PFS after immunotherapy compared with INMA.
Topics: Humans; Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Lung Neoplasms; Mucins; Mutation; Proto-Oncogene Proteins p21(ras); Retrospective Studies
PubMed: 37294384
DOI: 10.1007/s12032-023-02059-w -
The British Journal of Dermatology Jun 2003Abundant mucin deposition is an unusual finding in melanocytic naevi. We describe the first example, to our knowledge, of a sclerosing blue naevus with an abundant...
Abundant mucin deposition is an unusual finding in melanocytic naevi. We describe the first example, to our knowledge, of a sclerosing blue naevus with an abundant mucinous stroma in two unrelated patients. This uncommon variant of blue naevus should be differentiated from desmoplastic-neurotropic melanoma, in which the presence of mucin stromal deposition is a more typical finding.
Topics: Dendritic Cells; Female; Humans; Immunohistochemistry; Melanocytes; Middle Aged; Mucins; Nevus, Blue; Sclerosis; Skin Neoplasms; Staining and Labeling
PubMed: 12828757
DOI: 10.1046/j.1365-2133.2003.05353.x -
Methods in Molecular Biology (Clifton,... 2019Intraductal papillary mucinous neoplasms (IPMNs) characteristically consist of mucin-filled dilated ducts lined with neoplastic cells forming papillae with a diverse...
Intraductal papillary mucinous neoplasms (IPMNs) characteristically consist of mucin-filled dilated ducts lined with neoplastic cells forming papillae with a diverse range of morphologies and varying grades of atypia. Based on morphological characteristics and immunohistochemical reaction against mucin proteins, IPMNs are classified into four distinct subtypes: gastric, intestinal, pancreatobiliary, and oncocytic. In this chapter, histomorphological criteria and techniques of immunohistochemical staining and its evaluation for subtyping IPMNs are described.
Topics: Biomarkers, Tumor; Biopsy; Humans; Immunohistochemistry; Mucins; Pancreatic Intraductal Neoplasms
PubMed: 30378039
DOI: 10.1007/978-1-4939-8879-2_1 -
ChemPlusChem Dec 2020Mucins are bottlebrush biopolymers that are glycoproteins on the surfaces of cells and as hydrogels secreted inside and outside the body. Mucin function in biology... (Review)
Review
Mucins are bottlebrush biopolymers that are glycoproteins on the surfaces of cells and as hydrogels secreted inside and outside the body. Mucin function in biology includes cell-cell recognition, signaling, protection, adhesion, and lubrication. Because of their attractive and diverse properties, mucins have recently become the focus of synthetic efforts by researchers who hope to understand and emulate these biomaterials. This review is focused on the development of methodologies for preparing mucin-inspired synthetic oligomers and glycopolymers, including solid-phase synthesis, polymerization of glycosylated monomers, and post-polymerization grafting of glycans to polymer chains. How these synthetic mucins have been used in health applications is discussed. Natural mucins are formed from a conserved set of monomers that are combined into chains of different sequences and lengths to achieve materials with widely diverse properties. Adopting this design paradigm from natural mucins could lead to next-generation bioinspired synthetic materials.
Topics: Humans; Mucins; Polymers
PubMed: 33346954
DOI: 10.1002/cplu.202000637 -
Advanced Drug Delivery Reviews Nov 2021One of the main challenges in the field of drug delivery remains the development of strategies to efficiently transport pharmaceuticals across mucus barriers, which... (Review)
Review
One of the main challenges in the field of drug delivery remains the development of strategies to efficiently transport pharmaceuticals across mucus barriers, which regulate the passage and retention of molecules and particles in all luminal spaces of the body. A thorough understanding of the molecular mechanisms, which govern such selective permeability, is key for achieving efficient translocation of drugs and drug carriers. For this purpose, model systems based on purified mucins can contribute valuable information. In this review, we summarize advances that were made in the field of drug delivery research with such mucin-based model systems: First, we give an overview of mucin purification procedures and discuss the suitability of model systems reconstituted from purified mucins to mimic native mucus. Then, we summarize techniques to study mucin binding. Finally, we highlight approaches that made use of mucins as building blocks for drug delivery platforms or employ mucins as active compounds.
Topics: Animals; Drug Delivery Systems; Humans; Mucins
PubMed: 34166760
DOI: 10.1016/j.addr.2021.113845 -
Current Opinion in Chemical Biology Aug 2022Glycosylation, and especially O-linked glycosylation, remains a critical blind spot in the understanding of post-translational modifications. Due to their nature as... (Review)
Review
Glycosylation, and especially O-linked glycosylation, remains a critical blind spot in the understanding of post-translational modifications. Due to their nature as proteins defined by a large density and abundance of O-glycosylation, mucins present extra challenges in the analysis of their structure and function. However, recent breakthroughs in multiple areas of research have rendered mucin-domain glycoproteins more accessible to current characterization techniques. In particular, the adaptation of mucinases to glycoproteomic workflows, the manipulation of cellular glycosylation pathways, and the advances in synthetic methods to more closely mimic mucin domains have introduced new and exciting avenues to study mucin glycoproteins. Here, we summarize recent developments in understanding the structure and biological function of mucin domains and their associated glycans, from glycoproteomic tools and visualization methods to synthetic glycopeptide mimetics.
Topics: Glycopeptides; Glycoproteins; Glycosylation; Mucins; Polysaccharides
PubMed: 35752002
DOI: 10.1016/j.cbpa.2022.102174